Exelixis Inc. Common Stock vs Roivant Sciences Ltd. Common Shares — how do they compare? Exelixis Inc. Common Stock trades at $58.58 (market cap $14.48B), while Roivant Sciences Ltd. Common Shares trades at $34.21 (market cap $25.09B). The key difference: Roivant Sciences Ltd. Common Shares is the larger of the two by market cap, and Exelixis Inc. Common Stock is trading nearer its 52-week high, Roivant Sciences Ltd. Common Shares nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Exelixis Inc. Common Stock for 0 Days and Roivant Sciences Ltd. Common Shares for 0 Days on average.
| EXEL | ROIV | |
|---|---|---|
Market Cap | $14.48B | $25.09B |
Volume | 2,374,774 | 5,738,571 |
Sector | Health | Health |
52-Week High | $59.13 | $41.81 |
52-Week Low | $34.54 | $16.04 |
Typical Hold Time | 0 Days | 0 Days |
Enterprise Value | $13.81B | $21.36B |
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Exelixis develops and commercializes medicines for cancer. Its research focuses on targeted therapies for oncology.
Read more on EXEL →Roivant Sciences develops medicines by building and supporting biotechnology subsidiaries, known as Vants. Its programs span areas such as immunology, neuroscience, and rare diseases.
Read more on ROIV →